SEC Comment Letter 0000000000-23-000390 to Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc.
Date: Jan. 13, 2023 · CIK: 0001716947 · Accession: 0000000000-23-000390
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269157
Letter
United States securities and exchange commission logo January 13, 2023 Lynn Kirkpatrick, Ph.D. President, Chief Executive Officer & Director Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 Re:Ensysce Biosciences, Inc. Registration Statement on Form S-3 Filed January 9, 2023 File No. 333-269157 Dear Lynn Kirkpatrick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Eric Kline, Esq.
Show Raw Text
United States securities and exchange commission logo
January 13, 2023
Lynn Kirkpatrick, Ph.D.
President, Chief Executive Officer & Director
Ensysce Biosciences, Inc.
7946 Ivanhoe Avenue, Suite 201
La Jolla, California 92037
Re:Ensysce Biosciences, Inc.
Registration Statement on Form S-3
Filed January 9, 2023
File No. 333-269157
Dear Lynn Kirkpatrick:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Eric Kline, Esq.